Evidence map›Paper›PMID 35700034›Full record

SynthesisCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2022

Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma?

Angelica Macauda, Alyssa Clay-Gilmour, Thomas Hielscher, Michelle A T Hildebrandt, Marcin Kruszewski, Robert Z Orlowski, Shaji K Kumar, Elad Ziv, Enrico Orciuolo, Elizabeth E Brown and 46 more

Abstract readMeta-Analysis
In one paragraph

Synthesis in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

56 authors.

Angelica Macauda *Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0001-6895-6269
Alyssa Clay-Gilmour *Department of Epidemiology & Biostatistics, Arnold School of Public Health, University of South Carolina, Greenville, South Carolina.
Thomas HielscherDivision of Biostatistics, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany.
Michelle A T HildebrandtDepartment of Lymphoma - Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Marcin KruszewskiDepartment of Hematology University Hospital Bydgoszcz, Bydgoszcz, Poland.ORCID 0000-0001-8587-9621
Robert Z OrlowskiDepartment of Lymphoma - Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-5723-4129
Shaji K KumarDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0001-5392-9284
Elad ZivDepartment of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California.ORCID 0000-0002-2324-2884
Enrico OrciuoloClinical and Experimental Medicine, Section of Hematology, University of Pisa, Pisa, Italy.
Elizabeth E BrownDepartment of Pathology, School of Medicine, University of Alabama, Birmingham, Alabama.
Asta FörstiHopp Children's Cancer Center (KiTZ), Heidelberg, Germany.ORCID 0000-0002-9857-4728
Rosalie G WallerDivision of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0001-9437-8861
Mitchell J MachielaDivision of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.ORCID 0000-0001-6538-9705
Stephen J ChanockDivision of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.ORCID 0000-0002-2324-3393
Nicola J CampDivision of Hematology and Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-4788-1998
Marcin RymkoDepartment of Haematology and Bone Marrow Transplantation, SSM im. M. Kopernika, Torun, Poland.ORCID 0000-0002-6830-0240
Małgorzata RaźnyDepartment of Hematology, Rydygier Hospital, Cracow, Poland.ORCID 0000-0001-8503-6114
Wendy CozenDivision of Hematology/Oncology, Department of Medicine, School of Medicine, Department of Pathology, School of Medicine, Susan and Henry Samueli College of Health Sciences, Chao Family Comprehensive Cancer Center, University of California at Irvine, California.ORCID 0000-0003-3415-8247
Judit VárkonyiDepartment of Hematology and Internal Medicine, Semmelweis University, Budapest, Hungary.
Chiara PireddaGenomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-4797-8175
Matteo PelosiniClinical and Experimental Medicine, Section of Hematology, University of Pisa, Pisa, Italy.ORCID 0000-0002-4151-7132
Alem A BelachewDepartment of Lymphoma - Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-1369-799X
Edyta SuboczDepartment of Hematology, Military Institute of Medicine, Warsaw, Poland.ORCID 0000-0001-5225-3921
Kari HemminkiBiomedical Center, Faculty of Medicine, Charles University in Pilsen, Pilsen, Czech Republic.
Malwina Rybicka-RamosDepartment of Hematology Specialist Hospital No. 1 in Bytom, Bytom, Poland.
Graham G GilesCancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.ORCID 0000-0003-4946-9099
Roger L MilneCancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.ORCID 0000-0001-5764-7268
Jonathan N HofmannDivision of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
Jan Maciej ZauchaDepartment of Hematology and Transplantology, Medical Univeristy of Gdańsk, Gdańsk, Poland.ORCID 0000-0002-0986-8936
Annette Juul VangstedDepartment of Haematology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark.ORCID 0000-0002-2131-731X
Hartmut GoldschmidtDepartment of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.ORCID 0000-0003-0961-0035
S Vincent RajkumarDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-5862-1833
Waldemar TomczakDepartment of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Poland.ORCID 0000-0002-3205-5781
Juan SainzGenomic Oncology Area, GENYO. Centre for Genomics and Oncological Research: Pfizer, University of Granada/Andalusian Regional Government, Granada, Spain.ORCID 0000-0002-9355-2423
Aleksandra ButrymDepartment of Internal and Occupational Diseases, Medical University Wroclaw, Wroclaw, Poland.
Marzena WatekHematology Clinic, Holycross Cancer Center, Kielce, Poland.ORCID 0000-0002-3996-200X
Elżbieta Iskierka-JazdzewskaDepartment of Hematology, Medical University of Lodz, Lodz, Poland.ORCID 0000-0003-2772-8870
Gabriele BudaClinical and Experimental Medicine, Section of Hematology, University of Pisa, Pisa, Italy.ORCID 0000-0002-5240-5611
Dennis P RobinsonDivision of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
Artur JurczyszynPlasma Cell Dyscrasias Center, Department of Hematology, Faculty of Medicine, Jagiellonian University, Kraków, Poland.
Marek DudzińskiDepartment of Hematology, Institute of Medical Sciences, College of Medical Sciences, University of Rzeszów, Rzeszów, Poland.ORCID 0000-0001-5197-0785
Joaquin Martinez-LopezServicio de Hematología Centro de Actividades Ambulatorias, Madrid, Spain.ORCID 0000-0001-7908-0063
Jason P SinnwellDivision of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0003-1964-5522
Susan L SlagerDivision of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-5173-4712
Krzysztof JamroziakDepartment of Hematology, Transplantation and Internal Disease, Medical University of Warsaw, Warsaw, Poland.
Rui Manuel Vieira ReisLife and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal and ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal.ORCID 0000-0002-9639-7940
Niels WeinholdDepartment of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.ORCID 0000-0002-5464-3234
Parveen BhattiDivision of Population Oncology Cancer Control Research, BC Cancer, Vancouver, Bristish Columbia, Canada.ORCID 0000-0003-1709-1781
Luis G Carvajal-CarmonaDepartment of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis, Sacramento, California.ORCID 0000-0001-7129-2918
Daria ZawirskaDepartment of Hematology, University Hospital of Cracow, Cracow, Poland.ORCID 0000-0002-4732-8527
Aaron D NormanDivision of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
Grzegorz MazurDepartment of Internal and Occupational Diseases, Medical University Wroclaw, Wroclaw, Poland.ORCID 0000-0001-6610-2008
Sonja I BerndtDivision of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.ORCID 0000-0001-5230-0652
Daniele Campa *Department of Biology, University of Pisa, Pisa, Italy.
Celine M Vachon *Division of Epidemiology, Department of Quantitative Sciences, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-1962-9322
Federico Canzian *Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-4261-4583

Funding

Multidisciplinary Studies of LymphomaZIACP010170 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MORTON, LINDSAY · 2009 to 2025
$10.7M
Influence of germ line genetic variation on myeloma progression and survivalR21CA191896 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VACHON, CELINE M, ZIV, ELAD · 2015 to 2016
$407k
NCI NIH HHS R21 CA191896
6 · The paper itself

Abstract

backgroundGenome-wide association studies (GWAS) of multiple myeloma in populations of European ancestry (EA) identified and confirmed 24 susceptibility loci. For other cancers (e.g., colorectum and melanoma), risk loci have also been associated with patient survival.

methodsWe explored the possible association of all the known risk variants and their polygenic risk score (PRS) with multiple myeloma overall survival (OS) in multiple populations of EA [the International Multiple Myeloma rESEarch (IMMEnSE) consortium, the International Lymphoma Epidemiology consortium, CoMMpass, and the German GWAS] for a total of 3,748 multiple myeloma cases. Cox proportional hazards regression was used to assess the association between each risk SNP with OS under the allelic and codominant models of inheritance. All analyses were adjusted for age, sex, country of origin (for IMMEnSE) or principal components (for the others) and disease stage (ISS). SNP associations were meta-analyzed.

resultsSNP associations were meta-analyzed. From the meta-analysis, two multiple myeloma risk SNPs were associated with OS (P < 0.05), specifically POT1-AS1-rs2170352 [HR = 1.37; 95% confidence interval (CI) = 1.09-1.73; P = 0.007] and TNFRSF13B-rs4273077 (HR = 1.19; 95% CI = 1.01-1.41; P = 0.04). The association between the combined 24 SNP MM-PRS and OS, however, was not significant.

conclusionsOverall, our results did not support an association between the majority of multiple myeloma risk SNPs and OS. IMPACT: This is the first study to investigate the association between multiple myeloma PRS and OS in multiple myeloma.

Indexed as

Genome-Wide Association StudyMultiple MyelomaGenetic Predisposition to DiseaseHumansPolymorphism, Single NucleotideRisk Factors

Identifiers

PMID35700034
PMCPMC11375313

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.